BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24840631)

  • 1. B16 cell lysates plus polyinosinic-cytidylic acid effectively eradicate melanoma in a mouse model by acting as a prophylactic vaccine.
    Lin B; Zhao H; Fan J; Xie F; Wang W; Ding X
    Mol Med Rep; 2014 Aug; 10(2):911-6. PubMed ID: 24840631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T; Harada M; Tamada K; Abe K; Nomoto K
    Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of cytolytic CD8+ T cells in B16-melanoma and proliferation of mature T cells in TIS21-knockout mice after T cell receptor stimulation.
    Ryu MS; Woo MY; Kwon D; Hong AE; Song KY; Park S; Lim IK
    Exp Cell Res; 2014 Oct; 327(2):209-21. PubMed ID: 25088256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preliminary observation on antitumor effect of HPV58 composite DNA vaccine].
    Wang H; Yu JY; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):523-7. PubMed ID: 24284225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved.
    Wu TY; Fleischmann WR
    J Interferon Cytokine Res; 2001 Dec; 21(12):1117-27. PubMed ID: 11798470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with activated B cells pulsed with tumor-lysates can induce tumor-specific CD4+ T cells in vivo.
    Ito O; Harada M; Takenoyama M; Tamada K; Li T; Abe K; Fujie H; Nomoto K
    Immunobiology; 1998 Jul; 199(1):133-47. PubMed ID: 9717673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The opposite effect of tumor-infiltrating natural killer cells on in vivo priming of tumor-specific CD8+ T cells and CD4+ T cells.
    Terao H; Harada M; Kurosawa S; Shinomiya Y; Ito O; Tamada K; Takenoyama M; Nomoto K
    Immunobiology; 1996 Jul; 195(2):172-86. PubMed ID: 8877394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucin 1 and poly I:C activates dendritic cells and effectively eradicates pituitary tumors as a prophylactic vaccine.
    Sui D; Ma L; Li M; Shao W; Du H; Li K; Li Z; Li Z
    Mol Med Rep; 2016 Apr; 13(4):3675-83. PubMed ID: 26935338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibitory effect of 4-1BBL combined with Hsp70-tumor antigen peptides on pulmonary metastasis of melanoma in mice].
    Qiu H; Zhang GM; Zhang H; Yuan Y; Li D; Feng ZH
    Ai Zheng; 2005 Jul; 24(7):781-6. PubMed ID: 16004800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax.
    Mansour M; Pohajdak B; Kast WM; Fuentes-Ortega A; Korets-Smith E; Weir GM; Brown RG; Daftarian P
    J Transl Med; 2007 Apr; 5():20. PubMed ID: 17451606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration.
    Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
    J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
    Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
    Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells.
    Dezfouli S; Hatzinisiriou I; Ralph SJ
    Immunol Cell Biol; 2003 Dec; 81(6):459-71. PubMed ID: 14636243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
    Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O
    Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.